Drug Candidate Emricasan to Stop Progression of Liver Disease
Share
Follow Us
The Editors at Hepatitis Central
March 3, 2016
Learn how Emricasan, a first-in-class, orally active caspase protease inhibitor, offers the untapped medical need to stop liver fibrosis, nonalcoholic steatohepatitis (NASH) and cirrhosis.
San Diego-based Conatus takes aim at unmet medical need in cirrhosis
By Nicole Gray | March 2, 2016 Print
The approval of Gilead’s Sovaldi in December 2013 for oral treatment of hepatitis C (HCV) represented a major medical breakthrough. Not only did it provide HCV-infected patients with a vastly more effective treatment option than traditional interferon-based therapies, but Sovaldi was also curative in many cases.
The HCV market has only expanded since then as Gilead introduced Harvoni, followed by AbbVie’s VieKira Pak and Merck’s new drug Zepatier.
Continue reading this entire article:
http://www.biopharmadive.com/news/san-diego-based-conatus-takes-aim-at-unmet-medical-need-in-cirrhosis/414898/
